Dr James Patrick Buteau
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
52 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
From salvage to spotlight: how 2025 transformed PSMA radioligand therapy
DOI: 10.1111/bju.702822025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
DOI: 10.2967/jnumed.125.2696402025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82025
Journal article
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
DOI: 10.1038/s41591-025-03704-9
RECENT SCHOLARLY WORKS
2025
Journal article
Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
DOI: 10.2967/jnumed.124.2694472025
Journal article
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
DOI: 10.2967/jnumed.124.2686392025
Journal article
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
DOI: 10.2967/jnumed.124.268640